We discovered that in utero SSRI exposure is linked to an increased risk of the development of specific Disorders of gut-brain interaction (DGBI). We are now conducting a prospective clinical birth cohort study in pregnant women, infants and toddlers to investigate the mechanisms by which maternal SSRI exposure may increase the risk for DGBI development.